Abstract Background Musculoskeletal (MSK) involvement in IBD patients contributes to poorer outcomes and reduced quality of life (QoL). Recognising MSK involvement is important before initiating biologics, as their effects can differ between the gut, peripheral joints and spine. We aimed to describe the prevalence and distribution of peripheral and axial MSK symptoms and clinical findings in IBD patients starting biological treatment. Methods Bio-naïve IBD patients were consecutively recruited. Musculoskeletal symptoms were assessed using questionnaires and a structured interview. A rheumatologist conducted a clinical evaluation of peripheral joints, entheses, and spine mobility and considered various differential diagnoses. Results Of 82 patients (ulcerative colitis (UC): 33, Crohn’s disease (CD): 49), 51(62%) had musculoskeletal symptoms and 51(62%) had clinical findings (Table 1). Peripheral joint pain was reported by 39(48%) patients, usually affecting the hands, followed by the knees and ankles. Entheseal pain was present in 15(18%) patients, most often affecting the lateral hips, followed by the Achilles and patella tendons. Back pain was reported by 33(40%) patients. In 16 of these patients, the assessing rheumatologist could attribute the symptoms to competing differential diagnoses, such as degenerative spine disease (n=15), osteoarthritis (n=3) and overuse injury (n=2). Patients with CD suffered from significantly more MSK symptoms, particularly joint pain, compared to UC patients (67% vs. 40%, and 65% vs. 30%, respectively, p-values=0.01). Clinical evaluation revealed arthritis in 24(29%) patients and enthesitis in 50(61%). The small peripheral joints were predominantly involved in an oligo- and polyarticular pattern. Achilles tendon insertions were the most frequently affected entheses; enthesitis was asymptomatic in 72% of the cases. The Assessment of Spondyloarthritis international Society (ASAS) classification criteria for peripheral spondyloarthritis were met in 44% of patients; and for fibromyalgia in 8.5% of patients, all with clinically active IBD. Being female was associated with more frequent musculoskeletal symptoms and clinical findings. No other differences in clinical findings were observed between UC and CD, nor between those with active and inactive IBD. Patients with MSK involvement had significantly lower EQ-5D scores than those without. Conclusion Two-thirds of IBD patients scheduled for their first biological treatment exhibited musculoskeletal involvement, sometimes asymptomatically. Axial and peripheral symptoms were equally common. A multidisciplinary approach is crucial for early detection and integrated treatment aiming for remission in all disease domains to improve patients’ QoL.
Read full abstract